125742 S69 M1 356h

Pfizer Documents (PHMPT/FDA)

Pfizer Bla Submission

Pfizer 16 Plus Documents

7

Document text

08/19/2021
BioNTech Manufacturing GmbH
+49 (0) 6131 9084-7593 +49 (0) 6131 9084-390
An der Goldgrube 12
Mainz N/A
Germany 55131 [email protected]
117645848
2229
Elisa Harkins, Global Regulatory Lead, Pfizer Global Regulatory Affairs - Vaccines
500 Arcola Road
Collegeville PA
19426215-280-5503
845-474-3500
[email protected]
125742
[COVID-19 mRNA Vaccine (nucleoside modified)]
COMIRNATY
COVID-19 Vaccine (BNT162, PF-07302048)
Liquid 30 mcg Intramuscular
Active immunization to prevent COVID-19 caused by 
SARS-CoV-2 in individuals 16 years of age 
COVID-19; SARS-CoV-2; Disease caused by severe acute respiratory syndrome coronavirus 2; SARS-CoV-2 vaccination; COVID-19 vaccination
7
FDA-CBER-2021 5683-1078731
Response to FDA 19 August 2021 Information Request Regarding Safety-related Postmarketing Requirement/Postmarketing Commitment Studies
Pharmacia and Upjohn Company LLC (Pfizer)
7000 Portage Road
Kalamazoo MI
USA 490011810189
618054084
LNP production and bulk drug product formulation, Fill and finish, Primary packaging, Secondary packaging, 
Drug product testing
IND 19736, DMF 012683, DMF 9543, DMF 15209, DMF 011793, DMF 011820, DMF 011321, DMF 10953, 
7
(b) (6)
(b) (6)
(b) (6)
(b) (6)
(b) (6)
FDA-CBER-2021-5683-1078732
Response to FDA 19 August 2021 IR Regarding Safety-related Postmarketing Requirement/Postmarketing Commitment Studies
Elisa Harkins, Global Regulatory Lead, Global Regulatory Affairs - Vaccines, Pfizer Inc. 08/19/2021
215-280-5503 845-474-3500 [email protected]
500 Arcola Road
Collegeville PA
United States of America 19426
Elisa Harkins 
TullDigitally signed by Elisa Harkins Tull 
DN: o=Pfizer Inc, cn=Elisa Harkins Tull 
Reason: I attest to the accuracy and 
integrity of this document 
Date: 2021 08 19 15:46 53 -04'00'
7
FDA-CBER-2021-5683-1078733
Pfizer Manufacturing Belgium NV
Rijksweg 121000654629
Puurs N/A
Belgium 2870370156507
LNP production and bulk drug product formulation, Fill and finish, Primary packaging,  Secondary 
packaging, Drug product testing
Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC
1 Burtt Road1222181
Andover MA
United States 01810174350868
Manufacture of drug substance, Drug substance testing, Drug product testing
47
(b) (6)
(b) (6)
(b) (6)
(b) (6)
(b) (6)
(b) (6)
(b) (6)
(b) (6)
(b) (6)
(b) (6)
FDA-CBER-2021-5683-1078734
Pfizer Inc
875 Chesterfield Parkway West1940118
Chesterfield MO
United States 63017004954111
Drug substance testing, Drug product testing
Pfizer Ireland Pharmaceuticals
Grange Castle Business Park Clondalkin3004145594
Dublin 22 N/A
Ireland N/A985586408
Drug product testing
57
(b) (6)
(b) (6)
(b) (6)
(b) (6)
(b) (6)
(b) (6)
(b) (6)
(b) (6)
(b) (6)
(b) (6)
FDA-CBER-2021-5683-1078735
Hospira Zagrab Ltd.
Prudnicka cesta 603010630287
Prigorje Brdovecko
Croatia 10291500625201
Drug Product Release Testing (Sterility)
SGS Lab Simon SA
Vieux Chemin du Poete 103004186644
Wavre N/A
Belgium 1301283063907
Drug Product Release Testing (Sterility)
67
(b) (6)
(b) (6)
(b) (6)
(b) (6)
(b) (6)
(b) (6)
(b) (6)
(b) (6)
(b) (6)
(b) (6)
FDA-CBER-2021-5683-1078736
Fresenius Kabi USA LLC
Anthony Giessert
N/A
manufacture, testing and release of  diluent (0.9% Sodium chloride Injection, USP)
Hospira Inc.
Paul Lucas
manufacture, testing and release of  diluent (0.9% Sodium chloride Injection, USP)
77
(b) (4), (b) (6)
(b) (6)
(b) (4), (b) (6)
(b) (4), (b) (6)
(b) (6)
(b) (4), (b) (6)
(b) (4), (b) (6)
(b) (4)
(b) (4)
FDA-CBER-2021-5683-1078737